Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase
inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's
disease (AD).